Darbepoetin Alfa MDS Companion Protocol

Amgen

Status and phase

Completed

Phase 3

Conditions

Myelodysplastic Syndrome (MDS)

Treatments

Drug: Darbepoetin Alfa

Study type

Interventional

Funder types

Industry

Identifiers

NCT02175277

20130113

2013-000727-13 (EudraCT Number)

Details and patient eligibility

About

The primary objective of the study was to provide required access of investigational product (darbepoetin alfa) beyond the end of the active treatment period (EOATP) of the darbepoetin alfa MDS 20090160 (NCT01362140) study for patients who had continued demonstration of benefit from darbepoetin alfa treatment and to describe the safety of longer-term use in this patient population.

Full description

This is a phase 3b, multi-centre, open-label, single-arm companion study to the MDS 20090160 study (NCT01362140) for the treatment of anaemic patients with MDS. Participants who completed the active-treatment period of the darbepoetin alfa MDS 20090160 study and met the eligibility criteria could be enrolled into this study to continue treatment of darbepoetin alfa for up to 73 weeks or until progression to acute myelogenous leukemia (AML), whichever occurs first.

Enrollment

9 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subject or subject's legally acceptable representative has provided informed consent prior to any study-specific activities/ procedures being initiated;
Subject must continue long term follow up within parent study (20090160);
Subject must have an ongoing clinically relevant erythroid response as assessed by the Investigator using current response criteria (ie, International Working Group (IWG) response criteria);

Exclusion criteria

Transfusion dependence defined as receiving a total of ≥ 4 units of red blood cell (RBC) transfusion in the previous 8-week period prior to enrolment;
Known diagnosis of acute myelogenous leukemia (AML) or marrow collagen fibrosis;
Known refractory anaemia with excess blast-2 (RAEB-2);
Known diagnosis of intermediate-2 or high risk MDS per International Prognostic Scoring System (IPSS);
Subjects received thrombopoiesis-stimulating factors (eg, eltrombopag, romiplostim) in the MDS 20090160 study or planning to receive such agents during the study;
Other protocol defined inclusion and exclusion criteria may apply.